January 11th, 2010
COMPARE: Everolimus vs paclitaxel stents
Richard A. Lange, MD, MBA
In the recently published COMPARE trial, the use of second-generation everolimus-eluting stents, when compared with paclitaxel-eluting stents, was associated with a significant reduction in the risk of major adverse cardiac events at 1 year. This difference was driven by a reduction in the rate of MI and repeat target vessel revascularization. Interestingly, this reduction was already apparent at 1 month and attributable to a significantly lower rate of early stent thrombosis.
Based on these results, the authors suggest that paclitaxel-eluting stents should no longer be used in everyday clinical practice. Do you plan to stop using paclitaxel-eluting stents?
NEJM Journal Watch — Recent Cardiology Articles- To Lower Stroke Risk in Patients Undergoing Atrial Fibrillation Ablation, Is a Device or a Medication Better?
- Intensive vs. Standard Blood Pressure Lowering in Patients with Diabetes
- Anticoagulation in Patients with Cancer-Associated Pulmonary Embolism: How Long is Long Enough?
- Spironolactone Use After Percutaneous Intervention for Acute Myocardial Infarction
- CRISPR/Cas9 Gene Editing for Transthyretin Cardiomyopathy